Global Vaccines Administered Orally Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Table of Contents1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Vaccines Administered Orally Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Human
1.2.3 Animal
1.3 Market Segment by Application
1.3.1 Global Vaccines Administered Orally Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Vaccines Administered Orally Market Size (2017-2028)
2.1.1 Global Vaccines Administered Orally Revenue (2017-2028)
2.1.2 Global Vaccines Administered Orally Sales (2017-2028)
2.2 Global Vaccines Administered Orally Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Vaccines Administered Orally Sales by Regions (2017-2022)
2.2.2 Global Vaccines Administered Orally Revenue by Regions (2017-2022)
2.3 Global Vaccines Administered Orally Market Size Forecast by Region
2.3.1 Global Vaccines Administered Orally Sales Forecast by Region (2023-2028)
2.3.2 Global Vaccines Administered Orally Revenue Forecast by Region (2023-2028)
2.4 Global Top Vaccines Administered Orally Regions (Countries) Ranking by Market Size
2.5 Vaccines Administered Orally Market Dynamics
2.5.1 Vaccines Administered Orally Market Trends
2.5.2 Vaccines Administered Orally Market Drivers
2.5.3 Vaccines Administered Orally Market Challenges
2.5.4 Vaccines Administered Orally Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Vaccines Administered Orally Manufacturers by Sales (2017-2022)
3.1.1 Global Vaccines Administered Orally Sales by Manufacturers (2017-2022)
3.1.2 Global Vaccines Administered Orally Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Vaccines Administered Orally Sales in 2021
3.2 Global Top Manufacturers Vaccines Administered Orally by Revenue
3.2.1 Global Vaccines Administered Orally Revenue by Manufacturers (2017-2022)
3.2.2 Top Vaccines Administered Orally Manufacturers Covered: Ranking by Revenue
3.2.3 Global Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Vaccines Administered Orally Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccines Administered Orally as of 2021)
3.4 Global Vaccines Administered Orally Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Vaccines Administered Orally Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Vaccines Administered Orally Market
3.7 Key Manufacturers Vaccines Administered Orally Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Vaccines Administered Orally Market Size by Type
4.1 Global Vaccines Administered Orally Historic Market Review by Type (2017-2022)
4.1.1 Global Vaccines Administered Orally Sales Market Share by Type (2017-2022)
4.1.2 Global Vaccines Administered Orally Revenue Market Share by Type (2017-2022)
4.1.3 Vaccines Administered Orally Price by Type (2017-2022)
4.2 Global Vaccines Administered Orally Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Vaccines Administered Orally Sales Forecast by Type (2023-2028)
4.2.2 Global Vaccines Administered Orally Revenue Forecast by Type (2023-2028)
4.2.3 Vaccines Administered Orally Price Forecast by Type (2023-2028)
5 Global Vaccines Administered Orally Market Size by Application
5.1 Global Vaccines Administered Orally Historic Market Review by Application (2017-2022)
5.1.1 Global Vaccines Administered Orally Sales Market Share by Application (2017-2022)
5.1.2 Global Vaccines Administered Orally Revenue Market Share by Application (2017-2022)
5.1.3 Vaccines Administered Orally Price by Application (2017-2022)
5.2 Global Vaccines Administered Orally Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Vaccines Administered Orally Sales Forecast by Application (2023-2028)
5.2.2 Global Vaccines Administered Orally Revenue Forecast by Application (2023-2028)
5.2.3 Vaccines Administered Orally Price Forecast by Application (2023-2028)
6 North America
6.1 North America Vaccines Administered Orally Sales Breakdown by Company
6.1.1 North America Vaccines Administered Orally Sales by Company (2017-2022)
6.1.2 North America Vaccines Administered Orally Revenue by Company (2017-2022)
6.2 North America Vaccines Administered Orally Market Size by Type
6.2.1 North America Vaccines Administered Orally Sales by Type (2017-2028)
6.2.2 North America Vaccines Administered Orally Revenue by Type (2017-2028)
6.3 North America Vaccines Administered Orally Market Size by Application
6.3.1 North America Vaccines Administered Orally Sales by Application (2017-2028)
6.3.2 North America Vaccines Administered Orally Revenue by Application (2017-2028)
6.4 North America Vaccines Administered Orally Market Size by Country
6.4.1 North America Vaccines Administered Orally Sales by Country (2017-2028)
6.4.2 North America Vaccines Administered Orally Revenue by Country (2017-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Vaccines Administered Orally Sales Breakdown by Company
7.1.1 Europe Vaccines Administered Orally Sales by Company (2017-2022)
7.1.2 Europe Vaccines Administered Orally Revenue by Company (2017-2022)
7.2 Europe Vaccines Administered Orally Market Size by Type
7.2.1 Europe Vaccines Administered Orally Sales by Type (2017-2028)
7.2.2 Europe Vaccines Administered Orally Revenue by Type (2017-2028)
7.3 Europe Vaccines Administered Orally Market Size by Application
7.3.1 Europe Vaccines Administered Orally Sales by Application (2017-2028)
7.3.2 Europe Vaccines Administered Orally Revenue by Application (2017-2028)
7.4 Europe Vaccines Administered Orally Market Size by Country
7.4.1 Europe Vaccines Administered Orally Sales by Country (2017-2028)
7.4.2 Europe Vaccines Administered Orally Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Vaccines Administered Orally Sales Breakdown by Company
8.1.1 Asia Pacific Vaccines Administered Orally Sales by Company (2017-2022)
8.1.2 Asia Pacific Vaccines Administered Orally Revenue by Company (2017-2022)
8.2 Asia Pacific Vaccines Administered Orally Market Size by Type
8.2.1 Asia Pacific Vaccines Administered Orally Sales by Type (2017-2028)
8.2.2 Asia Pacific Vaccines Administered Orally Revenue by Type (2017-2028)
8.3 Asia Pacific Vaccines Administered Orally Market Size by Application
8.3.1 Asia Pacific Vaccines Administered Orally Sales by Application (2017-2028)
8.3.2 Asia Pacific Vaccines Administered Orally Revenue by Application (2017-2028)
8.4 Asia Pacific Vaccines Administered Orally Market Size by Region
8.4.1 Asia Pacific Vaccines Administered Orally Sales by Region
8.4.2 Asia Pacific Vaccines Administered Orally Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Vaccines Administered Orally Sales Breakdown by Company
9.1.1 Latin America Vaccines Administered Orally Sales by Company (2017-2022)
9.1.2 Latin America Vaccines Administered Orally Revenue by Company (2017-2022)
9.2 Latin America Vaccines Administered Orally Market Size by Type
9.2.1 Latin America Vaccines Administered Orally Sales by Type (2017-2028)
9.2.2 Latin America Vaccines Administered Orally Revenue by Type (2017-2028)
9.3 Latin America Vaccines Administered Orally Market Size by Application
9.3.1 Latin America Vaccines Administered Orally Sales by Application (2017-2028)
9.3.2 Latin America Vaccines Administered Orally Revenue by Application (2017-2028)
9.4 Latin America Vaccines Administered Orally Market Size by Country
9.4.1 Latin America Vaccines Administered Orally Sales by Country (2017-2028)
9.4.2 Latin America Vaccines Administered Orally Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Vaccines Administered Orally Sales Breakdown by Company
10.1.1 Middle East and Africa Vaccines Administered Orally Sales by Company (2017-2022)
10.1.2 Middle East and Africa Vaccines Administered Orally Revenue by Company (2017-2022)
10.2 Middle East and Africa Vaccines Administered Orally Market Size by Type
10.2.1 Middle East and Africa Vaccines Administered Orally Sales by Type (2017-2028)
10.2.2 Middle East and Africa Vaccines Administered Orally Revenue by Type (2017-2028)
10.3 Middle East and Africa Vaccines Administered Orally Market Size by Application
10.3.1 Middle East and Africa Vaccines Administered Orally Sales by Application (2017-2028)
10.3.2 Middle East and Africa Vaccines Administered Orally Revenue by Application (2017-2028)
10.4 Middle East and Africa Vaccines Administered Orally Market Size by Country
10.4.1 Middle East and Africa Vaccines Administered Orally Sales by Country (2017-2028)
10.4.2 Middle East and Africa Vaccines Administered Orally Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Merck Vaccines Administered Orally Products and Services
11.1.5 Merck Vaccines Administered Orally SWOT Analysis
11.1.6 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 GSK Vaccines Administered Orally Products and Services
11.2.5 GSK Vaccines Administered Orally SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Sanofi Vaccines Administered Orally Products and Services
11.3.5 Sanofi Vaccines Administered Orally SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Corporation Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Lanzhou Institute Vaccines Administered Orally Products and Services
11.4.5 Lanzhou Institute Vaccines Administered Orally SWOT Analysis
11.4.6 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Corporation Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Serum Institute Vaccines Administered Orally Products and Services
11.5.5 Serum Institute Vaccines Administered Orally SWOT Analysis
11.5.6 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Corporation Information
11.6.2 Valneva Overview
11.6.3 Valneva Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Valneva Vaccines Administered Orally Products and Services
11.6.5 Valneva Vaccines Administered Orally SWOT Analysis
11.6.6 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Corporation Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Shanghai United Cell Vaccines Administered Orally Products and Services
11.7.5 Shanghai United Cell Vaccines Administered Orally SWOT Analysis
11.7.6 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Corporation Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Bibcol Vaccines Administered Orally Products and Services
11.8.5 Bibcol Vaccines Administered Orally SWOT Analysis
11.8.6 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Corporation Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 PaxVax Vaccines Administered Orally Products and Services
11.9.5 PaxVax Vaccines Administered Orally SWOT Analysis
11.9.6 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Corporation Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Vabiotech Vaccines Administered Orally Products and Services
11.10.5 Vabiotech Vaccines Administered Orally SWOT Analysis
11.10.6 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Corporation Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Tiantan Biological Vaccines Administered Orally Products and Services
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Corporation Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 EuBiologics Vaccines Administered Orally Products and Services
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Corporation Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 Panacea Biotec Ltd Vaccines Administered Orally Products and Services
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Corporation Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Bio-Med Vaccines Administered Orally Products and Services
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.15.4 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Products and Services
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vaccines Administered Orally Value Chain Analysis
12.2 Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccines Administered Orally Production Mode & Process
12.4 Vaccines Administered Orally Sales and Marketing
12.4.1 Vaccines Administered Orally Sales Channels
12.4.2 Vaccines Administered Orally Distributors
12.5 Vaccines Administered Orally Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of TablesTable 1. Global Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Human
Table 3. Major Manufacturers of Animal
Table 4. Global Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Vaccines Administered Orally Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 6. Global Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 7. Global Vaccines Administered Orally Sales Market Share by Region (2017-2022)
Table 8. Global Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 9. Global Vaccines Administered Orally Revenue Market Share by Region (2017-2022)
Table 10. Global Vaccines Administered Orally Sales Forecast by Region (2023-2028) & (K Units)
Table 11. Global Vaccines Administered Orally Sales Market Share Forecast by Region (2023-2028)
Table 12. Global Vaccines Administered Orally Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 13. Global Vaccines Administered Orally Revenue Market Share Forecast by Region (2023-2028)
Table 14. Top Vaccines Administered Orally Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 15. Vaccines Administered Orally Market Trends
Table 16. Vaccines Administered Orally Market Drivers
Table 17. Vaccines Administered Orally Market Challenges
Table 18. Vaccines Administered Orally Market Restraints
Table 19. Global Vaccines Administered Orally Sales by Manufacturers (2017-2022) & (K Units)
Table 20. Global Vaccines Administered Orally Sales Share by Manufacturers (2017-2022)
Table 21. Global Vaccines Administered Orally Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 22. Ranking of Global Top Vaccines Administered Orally Manufacturers by Revenue (US$ Million) in 2021
Table 23. Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
Table 24. Global Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccines Administered Orally as of 2021)
Table 26. Key Manufacturers Vaccines Administered Orally Average Selling Price (ASP) & (2017-2022) & (US$/Unit)
Table 27. Key Manufacturers Vaccines Administered Orally Plants/Factories Distribution
Table 28. Key Manufacturers Vaccines Administered Orally Area Served
Table 29. Date of Key Manufacturers Enter into Vaccines Administered Orally Market
Table 30. Key Manufacturers Vaccines Administered Orally Product Type
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Vaccines Administered Orally Sales (K Units) by Type (2017-2022)
Table 33. Global Vaccines Administered Orally Sales Share by Type (2017-2022)
Table 34. Global Vaccines Administered Orally Revenue (US$ Million) Market Share by Type (2017-2022)
Table 35. Global Vaccines Administered Orally Price (K Units) by Type (2017-2022)
Table 36. Global Vaccines Administered Orally Sales (K Units) by Type (2023-2028)
Table 37. Global Vaccines Administered Orally Sales Share by Type (2023-2028)
Table 38. Global Vaccines Administered Orally Revenue (US$ Million) Market Share by Type (2023-2028)
Table 39. Global Vaccines Administered Orally Revenue Share by Type (2023-2028)
Table 40. Global Vaccines Administered Orally Price (K Units) by Type (2023-2028)
Table 41. Global Vaccines Administered Orally Sales (K Units) by Application (2017-2022)
Table 42. Global Vaccines Administered Orally Sales Share by Application (2017-2022)
Table 43. Global Vaccines Administered Orally Revenue (US$ Million) Market Share by Application (2017-2022)
Table 44. Global Vaccines Administered Orally Price (K Units) by Application (2017-2022)
Table 45. Global Vaccines Administered Orally Sales (K Units) by Application (2023-2028)
Table 46. Global Vaccines Administered Orally Sales Share by Application (2023-2028)
Table 47. Global Vaccines Administered Orally Revenue (US$ Million) Market Share by Application (2023-2028)
Table 48. Global Vaccines Administered Orally Revenue Share by Application (2023-2028)
Table 49. Global Vaccines Administered Orally Price (K Units) by Application (2023-2028)
Table 50. North America Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 51. North America Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 52. North America Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 53. North America Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 54. North America Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 55. North America Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 56. North America Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 57. North America Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 58. North America Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 59. North America Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 60. North America Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 61. North America Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 62. North America Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 63. North America Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 64. North America Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 65. North America Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 66. Europe Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 67. Europe Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 68. Europe Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 69. Europe Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 70. Europe Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 71. Europe Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 72. Europe Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 73. Europe Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 74. Europe Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 75. Europe Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 76. Europe Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 77. Europe Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 78. Europe Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 79. Europe Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 80. Europe Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 81. Europe Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 82. Asia Pacific Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 83. Asia Pacific Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 84. Asia Pacific Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 85. Asia Pacific Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 86. Asia Pacific Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 87. Asia Pacific Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 88. Asia Pacific Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 89. Asia Pacific Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 90. Asia Pacific Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 91. Asia Pacific Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 92. Asia Pacific Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 93. Asia Pacific Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 94. Asia Pacific Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
Table 95. Asia Pacific Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
Table 96. Asia Pacific Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
Table 97. Asia Pacific Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
Table 98. Latin America Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 99. Latin America Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 100. Latin America Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 101. Latin America Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 102. Latin America Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 103. Latin America Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 104. Latin America Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 105. Latin America Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 106. Latin America Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 107. Latin America Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 108. Latin America Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 109. Latin America Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 110. Latin America Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 111. Latin America Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 112. Latin America Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 113. Latin America Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 114. Middle East and Africa Vaccines Administered Orally Sales by Company (2017-2022) & (K Units)
Table 115. Middle East and Africa Vaccines Administered Orally Sales Market Share by Company (2017-2022)
Table 116. Middle East and Africa Vaccines Administered Orally Revenue by Company (2017-2022) & (US$ Million)
Table 117. Middle East and Africa Vaccines Administered Orally Revenue Market Share by Company (2017-2022)
Table 118. Middle East and Africa Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
Table 119. Middle East and Africa Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
Table 120. Middle East and Africa Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
Table 121. Middle East and Africa Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
Table 122. Middle East and Africa Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
Table 123. Middle East and Africa Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
Table 124. Middle East and Africa Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
Table 125. Middle East and Africa Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
Table 126. Middle East and Africa Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
Table 127. Middle East and Africa Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
Table 128. Middle East and Africa Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
Table 129. Middle East and Africa Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
Table 130. Merck Corporation Information
Table 131. Merck Description and Overview
Table 132. Merck Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 133. Merck Vaccines Administered Orally Product and Services
Table 134. Merck Vaccines Administered Orally SWOT Analysis
Table 135. Merck Recent Developments
Table 136. GSK Corporation Information
Table 137. GSK Description and Overview
Table 138. GSK Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 139. GSK Vaccines Administered Orally Product and Services
Table 140. GSK Vaccines Administered Orally SWOT Analysis
Table 141. GSK Recent Developments
Table 142. Sanofi Corporation Information
Table 143. Sanofi Description and Overview
Table 144. Sanofi Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 145. Sanofi Vaccines Administered Orally Product and Services
Table 146. Sanofi Vaccines Administered Orally SWOT Analysis
Table 147. Sanofi Recent Developments
Table 148. Lanzhou Institute Corporation Information
Table 149. Lanzhou Institute Description and Overview
Table 150. Lanzhou Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 151. Lanzhou Institute Vaccines Administered Orally Product and Services
Table 152. Lanzhou Institute Vaccines Administered Orally SWOT Analysis
Table 153. Lanzhou Institute Recent Developments
Table 154. Serum Institute Corporation Information
Table 155. Serum Institute Description and Overview
Table 156. Serum Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 157. Serum Institute Vaccines Administered Orally Product and Services
Table 158. Serum Institute Vaccines Administered Orally SWOT Analysis
Table 159. Serum Institute Recent Developments
Table 160. Valneva Corporation Information
Table 161. Valneva Description and Overview
Table 162. Valneva Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 163. Valneva Vaccines Administered Orally Product and Services
Table 164. Valneva Vaccines Administered Orally SWOT Analysis
Table 165. Valneva Recent Developm